Hong Kong approves Leqembi, the first Alzheimer's treatment to slow cognitive decline.
Hong Kong has approved Leqembi (lecanemab), a treatment for Alzheimer's disease, becoming the fifth country to do so, following the US, Japan, China, and South Korea. Leqembi is the first treatment to reduce the progression rate of Alzheimer's and slow cognitive and functional decline by selectively binding to amyloid-beta aggregates. The approval is based on the results of the large global Phase 3 Clarity AD study.
July 11, 2024
3 Articles